Skip to main content
. 2022 Feb 25;9(4):ofac098. doi: 10.1093/ofid/ofac098

Table 2.

Features at Medium-term Follow-up (≤180 Days From Initial Symptoms)

Clinical Characteristics Severe Disease (n = 143) Moderate Disease (n = 162) P Valuea
Symptom resolution, % 13.08 14.06 .817
Symptoms, %
-Cough 14.41 26.32 .033
-Chest pain 24.11 31.37 .235
-Asthenia 29.46 37.00 .244
-Memory loss 10.48 4.55 .125
-Hair loss 16.51 6.59 .032
Dyspnea mMRC, mean (SD), No. 1.45 (0.07) 1.33 (0.06) .143
Dyspnea mMRC ≥2, % 55.55 44.09 .042
Crackly, % 16.52 8.33 .090
Average time,b median (IQR), d 135 (116–153) 133 (116–158) .777
Radiological Features Severe Disease (n = 139) Moderate Disease (n = 157)
Normal radiological pattern, % 41.86 76.30 .001
RALE score, mean (SD) 0.62 (0.14) 0.12 (0.06) .002
RALE score 0, % 85.27 95.56 .033
Pulmonary opacities, % 42.15 13.11 .001
Bands or reticulations, % 33.06 14.75 .001
Hypoattenuation, % 5.79 5.00 .506
Average time,b median (IQR), d 119 (91–144) 93 (61–128) .001
Pulmonary Functional Data Severe Disease (n = 79) Moderate Disease (n = 82)
Functional data normalization, % 40.51 59.76 <.001
FEV1, mean (SD), % predicted 92.58 (20.51) 99.83 (20.88) .048
FVC, mean (SD), % predicted 94.90 (25.71) 102.89 (20.93) .036
FEV/FVC, mean (SD) 76.83 (12.67) 75.98 (1.40) .681
SpO2, mean (SD), % 96.02 (1.86) 96.81 (11.65) .002
DLCO, mean (SD), % predicted 70.84 (21.35) 82.60 (25.73) <.001
Average time,b median (IQR), d 138 (117–156) 131 (109–147) .271
Serum Biomarkers Severe Disease (n = 86) Moderate Disease (n = 97)
Lactate dehydrogenase, median (IQR), U/L 387 (347–442) 387 (327–415) .180
Ferritin, median (IQR), ng/mL 88 (39–173) 65 (34.5– 110) .287
D-dimer, median (IQR), ng/mL 432 (278–742) 350.5 (219–597) .023
D-dimer >500 ng/mL, % 37.35 33.33 .347
Average time,b median (IQR), d 120 (109–130) 115 (107–122) .445

Abbreviations: DLCO, diffusion capacity for carbon monoxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; IQR, interquartile range; mMRC, modified Medical Research Council; RALE, Radiographic Assessment of Lung Edema; SpO2, oxygen saturation.

P values from 2-sample t test, Wilcoxon rank-sum test, chi-square test, or Fisher exact test. Average time from initial symptoms to evaluation.

time from initial symptoms to the follow-up data.